TELA Bio, Inc.
TELA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.13 | -0.23 | -1.77 |
| FCF Yield | -49.43% | -27.39% | -22.78% | -16.77% |
| EV / EBITDA | -2.37 | -3.59 | -4.74 | -5.93 |
| Quality | ||||
| ROIC | -47.16% | -70.85% | -69.49% | -56.67% |
| Gross Margin | 67.08% | 68.62% | 65.30% | 63.85% |
| Cash Conversion Ratio | 1.10 | 0.88 | 0.92 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.72% | 25.65% | 31.50% | 24.02% |
| Free Cash Flow Growth | -2.69% | 2.70% | -37.22% | -26.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.35 | 0.14 | 0.05 | 0.43 |
| Interest Coverage | -6.45 | -8.44 | -9.63 | -8.19 |
| Efficiency | ||||
| Inventory Turnover | 1.78 | 1.39 | 1.22 | 1.39 |
| Cash Conversion Cycle | 223.33 | 289.56 | 318.83 | 232.18 |